Bipartisan Support For Comparative Efficacy Policy Likely To Grow - McClellan
This article was originally published in The Pink Sheet Daily
Increasing interest in demonstrating safety, efficacy and value of medications will drive development of policies around comparative evidence, the former FDA head predicts.
You may also be interested in...
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.